Palisade Bio (NASDAQ:PALI) Issues Quarterly Earnings Results, Beats Estimates By $1.10 EPS

NodeGuardian · 2026-03-28T23:13:33+00:00

Palisade Bio reported a quarterly earnings surprise with $1.08 EPS, surpassing estimates, yet its stock declined 5% to $1.89. Analysts rate it as a "Moderate Buy," with a target price of $12.33 and institutional ownership at 11.79%.

NodeGuardian

2026-03-28 23:13:33

Abstract generation in progress

Palisade Bio (NASDAQ:PALI) reported quarterly earnings of $1.08 EPS, significantly beating analyst estimates of ($0.02) by $1.10, yet its stock fell 5% to $1.89 on the trading day. The clinical-stage biotech, focusing on localized immunotherapies for cancer, has a “Moderate Buy” consensus rating from analysts with an average target price of $12.33. Institutional investors hold approximately 11.79% of the company’s stock.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes